
Sarepta Therapeutics (SRPT) Stock Forecast & Price Target
Sarepta Therapeutics (SRPT) Analyst Ratings
Bulls say
Sarepta Therapeutics is expected to experience long-term success due to its focused approach on rare genetic diseases, diverse portfolio of approved treatments for neuromuscular disorders, and ongoing investments in research and development for future therapeutics. While the company carries a significant amount of debt, its strong cash position and continued commercial success of its current products justify its current valuation. However, potential risks such as uncertainties around FDA approvals and increasing competition in the market could impact the company's future performance.
Bears say
Sarepta Therapeutics is facing challenges in proving the efficacy of its treatments, as it has increasingly relied on external controls and non-randomized comparisons to showcase their benefits. Furthermore, the company's guide range for 2026 suggests a decline in revenues, and there are concerns about their ability to gain payer adoption and generate demand for their products. The recent shift towards heavier commercial execution also raises questions about the sustainability of their current trajectory. Overall, the financial and data metrics suggest a concerning outlook for Sarepta Therapeutics' stock.
This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Sarepta Therapeutics (SRPT) Analyst Forecast & Price Prediction
Start investing in Sarepta Therapeutics (SRPT)
Order type
Buy in
Order amount
Est. shares
0 shares